wire - news in brief

« BACK

Administration/Government



Results 1 - 50 of 178.
1 2 3 4 Next »

Medicine/Pharmacology - Administration/Government
16.04.2018
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes Heart failure (HF) patients with reduced
Life Sciences - Administration/Government
10.04.2018
Researcher Granted EUR 2.5 Million in Funding
Each year the European Research Council (ERC), open to both junior and established researchers, awards substantial funding for outstanding fundamental research.
Medicine/Pharmacology - Administration/Government
28.03.2018
Administration/Government - Business/Economics
09.03.2018
Innovation/Technology - Administration/Government
07.03.2018
Connected vehicle tech: Mandate now to save lives
ANN ARBOR-Up to 8.1 million car crashes and 44,000 deaths could be prevented if the federal government mandated connected vehicle technology now, rather than waiting even three years to develop and evaluate competing technologies.
Innovation/Technology - Administration/Government
05.03.2018
Medicine/Pharmacology - Administration/Government
27.02.2018
European Commission approves Roche’s Hemlibra for people with haemophilia A with inhibitors
European Commission approves Roche's Hemlibra for people with haemophilia A with inhibitors First new medicine in over 20 years to treat people with haemophilia A with inhibitors in Europe Hemlibra d
Innovation/Technology - Administration/Government
27.02.2018
Medicine/Pharmacology - Administration/Government
14.02.2018
Medicine/Pharmacology - Administration/Government
13.02.2018
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis
Sandoz announces US FDA approval and launch of Glatopa 40 mg/mL three times-a-week generic option for relapsing forms of multiple sclerosis Glatopa 40 mg/mL is a fully substitutable, AP-rated generic
Environment/Sustainable Development - Administration/Government
29.01.2018
Calculating the CO2 emissions of biofuels is not enough
A new EU regulation aims to shrink the environmental footprint of biofuels starting in 2021. But an EPFL scientist thinks we should go one step further and take into account all compounds produced at biorefineries, not just biofuel.
Medicine/Pharmacology - Administration/Government
26.01.2018
Advanced Accelerator Applications Receives FDA Approval for Lutathera for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT)   Advanced Accelerator Applications is a newly established subsidiary of Novartis   Lutathera expands Novartis' n
Administration/Government - Innovation/Technology
23.01.2018
Astronomy - Administration/Government
17.01.2018
Investigation launched
ETH Zurich's Executive Board has launched an investigation into allegations of research misconduct by a professor in the former Institute for Astronomy.
Administration/Government - Careers/Employment
04.01.2018
Medicine/Pharmacology - Administration/Government
22.12.2017
Novartis’ combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma
Novartis' combination therapy Tafinlar + Mekinist granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma Priority Review designation based on Phase I
Law/Forensics - Administration/Government
11.12.2017
Ontario Should Revise Discriminatory Policy Against Refugee Drivers
Allow experienced drivers from war-torn countries to skip driving-test waiting period similar to other newcomers in Ontario Toronto, ON - Ontario's Ministry of Transportation should revise its policy
Medicine/Pharmacology - Administration/Government
06.12.2017
Personalized Health: National Funding for Basel-led Research Groups
Personalized Health: National Funding for Basel-led Research Groups
Nine research projects involving Basel-based researchers in the field of personalized health are to receive funding from the Swiss government: support will be given to researchers from the University
Administration/Government - Physics/Materials Science
22.11.2017
Driving into danger with the blue lights flashing
The PSI radiation protection service is responsible for missions not only at the Institute, but throughout the canton of Aargau.
Medicine/Pharmacology - Administration/Government
15.11.2017
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania
Objective is to provide patients with rapid cancer diagnostics and appropriate care First focus will be on Ethiopia, Uganda and Tanzania Cancer is on the rise in Africa, with more than 500,000 deaths
Innovation/Technology - Administration/Government
15.11.2017
Medicine/Pharmacology - Administration/Government
11.11.2017
Punjab province in Pakistan signs agreement with Novartis Access against chronic diseases
Poor patients in Punjab will have access to high-quality  medicines against noncommunicable, chronic diseases thanks to agreement between government and Novartis Access Punjab government will make m
Medicine/Pharmacology - Administration/Government
01.11.2017
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting
Roche to present new data across a range of blood diseases at the American Society of Hematology (ASH) 2017 Annual Meeting Further results from emicizumab phase III studies in people with haemophilia
Administration/Government - Astronomy
25.10.2017
Administrative enquiry opened
ETH Zurich is launching an administrative enquiry into allegations made in the Department of Physics.
Medicine/Pharmacology - Administration/Government
23.10.2017
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
Novartis combination adjuvant therapy Tafinlar + Mekinist receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients Breakthrough Therapy Designation ba
Medicine/Pharmacology - Administration/Government
10.10.2017
Medicine/Pharmacology - Administration/Government
06.10.2017
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus
FDA approves Roche cobas Zika as first commercially-available donor screening test for Zika virus Zika virus infection is linked to neurological complications in adults, and brain defects in fetuses
Environment/Sustainable Development - Administration/Government
06.10.2017
Instrument of ratification deposited: Paris climate agreement to enter into force for Switzerland on 5 November 2017
Bern, 06.10.2017 - Switzerland deposited its instrument of ratification in New York on 6 October 2017, making it an official party to the Paris Agreement.
Administration/Government
29.09.2017
Medicine/Pharmacology - Administration/Government
22.09.2017
Novartis and The Max Foundation transform pioneering cancer access program for people in lower-income countries
CMLPath to Care(TM) collaboration replaces Glivec International Patient Access Program (GIPAP) with a new, independent, patient-centered access model   GIPAP was introduced 15 years ago and has provi
Administration/Government - Agronomy/Food Science
29.08.2017
Administration/Government - Medicine/Pharmacology
23.08.2017
Switzerland once again a full member of partnership-funded EU innovation programmes
Bern, 23.08.2017 - On 23 August, the Federal Council approved the agreements on Switzerland's participation in the Eurostars-2 and the Active and Assisted Living research and development programmes.
Business/Economics - Administration/Government
15.08.2017
The smart grid analysts
The smart grid analysts
ETH spin-off Adaptricity has developed a piece of software that can be used to analyse the increasingly intelligent power grids.
Administration/Government
11.07.2017
Use-inspired basic research: external report recommends targeted adjustments
Use-inspired basic research: external report recommends targeted adjustments
The Swiss National Science Foundation (SNSF) commissioned an external evaluation of its funding category "use-inspired basic research" last year. Based on the evaluators' recommendations, it has now decided to introduce targeted changes in its processes. Based on a mandate from the federal government, the Swiss National Science Foundation promotes scientific research; the focus is on basic research.
Medicine/Pharmacology - Administration/Government
10.07.2017
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine
Positive phase III results for Roche's emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate by 79% compared to prior prophylactic bypassing agents Data from HAVEN 1 in adults and adolescents and inte
Administration/Government - Careers/Employment
06.07.2017
Ten years of the European Research Council: positive record from Swiss perspective
Bern, 06.07.2017 - An event was held in Geneva on 6 July to mark the tenth anniversary of the European Research Council (ERC).
Medicine/Pharmacology - Administration/Government
27.06.2017
Fewer pills, more flexibility in dosing: Roche’s new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF)
Fewer pills, more flexibility in dosing: Roche's new Esbriet tablet formulation approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF) New immediate-release tablet formulation of
Administration/Government
08.06.2017
Mobilizing Swiss Research in Asia
Mobilizing Swiss Research in Asia
ETH Zurich to serve as the Leading House for Swiss Science and Technology programme in the Asia-Pacific region.
Medicine/Pharmacology - Administration/Government
05.06.2017
Rocheâ? s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer
APHINITY study shows Rocheâ??s Perjeta-based regimen reduced the risk of invasive cancer returning compared to Herceptin and chemotherapy in HER2-positive early breast cancer Phase III study confirms
Media - Administration/Government
02.06.2017
Medicine/Pharmacology - Administration/Government
24.05.2017
New data at ATS add to the body of evidence for Roche’s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF)
New data at ATS add to the body of evidence for Roche's Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet reduced the risk of death in p
Administration/Government - Careers/Employment
17.05.2017
Stable demand for SNSF funding
Stable demand for SNSF funding
In 2016, the Swiss National Science Foundation (SNSF) supported around 3200 research projects involving more than 14,000 researchers from universities, universities of applied sciences, universities
Medicine/Pharmacology - Administration/Government
10.05.2017
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer
Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer IMvigor211 study did not meet its primary endpoint of overall survival (
1 2 3 4 Next »